Rodman initiates Hana Biosciences at market outperform

Hana Biosciences Inc. coverage was initiated by Rodman & Renshaw LLC analyst Reni Benjamin with a market outperform rating and an $11 price target. Shares of the South San Francisco, Calif., biopharmaceutical company were up 19 cents, or 3.33%, at $5.89 on volume of 222,300 shares. A three-month average of share volume was unavailable.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.